Table 2. Base-case model results using DURATION-6 trial clinical inputs.

Strategy	Drug Cost	Adverse Event Cost	Discontinuation Cost	Total Cost	HbA1c Reduction	ICER
Liraglutide QD 1.8 mg	$3,077	$432	$0	$3,509	–1.54%	-
Exenatide QW 2 mg	$2,345	$273	$0	$2,618	–1.36%	-
Difference	$732	$159	$0	$891	0.19%	$4,773

HbA1c = glycated hemoglobin; ICER = incremental cost-effectiveness ratio; QD = once daily; QW = once weekly

The liraglutide incremental cost-effectiveness ratio (ICER) indicates that strategy is expected to cost $4,773 for a 1% reduction in HbA1c relative to the exenatide strategy.